Harnessing the immune system to attack cancer cells has represented a holy grail for
greater than 100 years. While prospects of tumor-selective durable immune based therapies
have provided small clinical signals for many decades, recent years have demonstrated a
virtual explosion in progress. Melanoma has led the field of cancers in which
immunotherapy has produced major clinical inroads. The most significant and impactful
immunotherapies for melanoma utilize immune checkpoint inhibition to stimulate T cell …